Similar articles

• Pharmacotherapy of triple-negative breast cancer.

  Arslan C, Dizdar O, Altundag K. Arslan C, et al. Expert Opin Pharmacother. 2009 Sep;10(13):2081-93. doi: 10.1517/14656560903117309. Expert Opin Pharmacother. 2009. PMID: 19640211 Review.
• Search for new treatments intensifies for triple-negative breast cancer.

  Brower V. Brower V. J Natl Cancer Inst. 2009 Nov 18;101(22):1536-7. doi: 10.1093/jnci/djp422. Epub 2009 Oct 30. J Natl Cancer Inst. 2009. PMID: 19880812 No abstract available.
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Gelmon KA, et al. Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19. Lancet Oncol. 2011. PMID: 21862407 Clinical Trial.
• Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations.

  Pristauz G, Petru E, Stacher E, Geigl JB, Schwarzbraun T, Tsybrovskyy O, Winter R, Moinfar F. Pristauz G, et al. Histopathology. 2010 Dec;57(6):877-84. doi: 10.1111/j.1365-2559.2010.03724.x. Histopathology. 2010. PMID: 21166701
• What is triple-negative breast cancer?

  Irvin WJ Jr, Carey LA. Irvin WJ Jr, et al. Eur J Cancer. 2008 Dec;44(18):2799-805. doi: 10.1016/j.ejca.2008.09.034. Epub 2008 Nov 12. Eur J Cancer. 2008. PMID: 19008097 Review.